Coagulo Medical Technologies Inc. raised $6.5 million in financing to accelerate delivery of its precision-medicine coagulation diagnostics platform. 20/20 Healthcare Partners led the investment with participation from Sands Capital, Good Growth Capital, IAG Capital Partners, and private investors. The company also received funding through a Small Business Innovation Research (SBIR) grant from the National Science Foundation to develop a COVID-19-related coagulation test.
TORONTO – It took the Vancouver, British Columbia-based biotech three times, but before the week in mid-December was over, Abcellera Biologics Inc. had finally closed its IPO on the Nasdaq, hoovering up gross proceeds of $555.5 million.
TORONTO – Waterloo, Ontario-based health startup Kenota Inc. has raised $9 million in series A funding to develop an in-clinic allergy test that takes less than 30 minutes and requires only a few drops of blood from a mild finger prick. This brings the total investment to $11 million for a point-of-care system that detects antibodies signaling allergies to egg, milk and peanuts and that will eventually search out environmental allergies to bee stings and shellfish.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Clarity, HBM, Junshi, Phathom, Revitope Oncology, Sellas Life Sciences, Takeda.
Shares in Chinese drug developer Jacobio Pharmaceuticals Group Co. Ltd. (HK:1167) rose 3% on their first day of trading in Hong Kong. The company, which develops small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, raised HK$1.35 billion (US$174.1 million) in its IPO, pricing 96 million shares at HK$14. Shares closed at HK$14.42 on Dec. 21 after rising as high as HK$16.50.
RSS
